Transthyretin (TTR) stabilizers: The safety and efficacy of tafamidis in delaying neurologic disease progression in patients with early-stage ATTRv-PN (stage 1) have been demonstrated in several clinical trials, extension studies [95], and around 10 years of clinical follow-up [18]. The gene discussed is TTR; the disease is poikiloderma with neutropenia.